• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer

    FIERCE PHARMA

    Tortugas Comes Out Of Shell With $106M, 4 Ph. 2-Stage Neuro Meds

    FIERCE BIOTECH

    Eisai To Present Real-World Lecanemab Data For Early Alzheimer

    PR NEWSWIRE

    Eisai, Nuvation Bio Seek Ema Approval For Taletrectinib In Cancer

    PR NEWSWIRE

    Merck`s Welireg combos deliver 1-2 punch to kidney cancer

    FIERCE PHARMA

    Eisai, Henlius Ink Exclusive Deal For Anti-PD-1 Antibody In Japan

    PR NEWSWIRE

    Eisai Invests $8.8M In Malaria, Tuberculosis, And NTD R&D Project

    PR NEWSWIRE

    Eisai Seeks EMA Approval For Leqembi IV Maintenance Dosing

    PR NEWSWIRE

    FDA Accepts LEQEMBI IQLIK sBLA as a Subcutaneous

    GLOBENEWSWIRE

    Eisai`s EA Pharma Starts Phase III Trial For Evenamide

    PHARMIWEB

    BLA For Subcutaneous Formulation Of Leqembi Accepted In China

    PR NEWSWIRE

    China Accepts BLA for Subcutaneous LEQEMBI in Early Alzheimer

    GLOBENEWSWIRE

    Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau

    BIOSPACE

    Eisai Reveals Extended Benefits Of LEQEMBI In Early Alzheimer

    GLOBENEWSWIRE

    Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan

    GLOBENEWSWIRE

    Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases

    PR NEWSWIRE

    Eisai To Share Lecanemab Data At 18th CTAD Conference

    PR NEWSWIRE

    UK Approves Leqembi Iv for Early Alzheimer`s Disease

    GLOBENEWSWIRE

    Eisai Shows Dedication To Advanced Endometrial Cancer Care

    PR NEWSWIRE

    Leqembi Iqlik Maintenance Treatment Launched In U.S.

    PR NEWSWIRE

    China Approves `leqembi` Maintenance Dosing For Early Alzheimer

    GLOBENEWSWIRE

    Four-Year LEQEMBI® Data Shows Benefit in Early Alzheimer’s

    PR NEWSWIRE

    TGA Declines Registration Of Lecanemab In Australia

    PR NEWSWIRE

    EU Reaffirms Positive Opinion for Eisai-Biogen Alzheimer’s Drug

    REUTERS

    BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

    FIERCE BIOTECH

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.